<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574548</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3010</org_study_id>
    <secondary_id>B1851027</secondary_id>
    <nct_id>NCT00574548</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety, tolerability and immunologic response
      to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that
      have never received a previous dose of 23vPS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)</measure>
    <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)</measure>
    <time_frame>1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)</measure>
    <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)</measure>
    <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Pneumococcal Vaccines</condition>
  <arm_group>
    <arm_group_label>Group 1.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1.1 = 13vPnC then 13vPnC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1.2 = 13vPnC then 23vPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 = 23vPS then 13vPnC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13 valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1</description>
    <arm_group_label>Group 1.1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13 valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1</description>
    <arm_group_label>Group 1.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13 valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent Pneumococcal Polysaccharide Vaccine</intervention_name>
    <description>0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent Pneumococcal Polysaccharide Vaccine</intervention_name>
    <description>0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1</description>
    <arm_group_label>Group 1.2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female, aged 60 to 64 years.

          -  Healthy.

        Exclusion Criteria:

          -  Previous vaccination with any licensed or experimental pneumococcal vaccine.

          -  History of severe adverse reaction associated with a vaccine.

          -  Immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3010&amp;StudyName=Study%20Evaluating%20the%20Safety%2C%20Tolerability%20and%20Immunogenicity%20of%2013vPnC%20as%20a%202-Dose%20Regimen%20or%20with%2023vPS</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <results_first_submitted>February 1, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2011</results_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc</organization>
  </responsible_party>
  <keyword>Vaccines, Pneumococcal Conjugate Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC - Group 1.1 or 1.2</title>
          <description>Group 1.1: 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1; or Group 1.2: 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="P2">
          <title>23vPS - Group 2</title>
          <description>Group 2: 23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="482"/>
                <participants group_id="P2" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1 (Vax 1)</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Vax 1 (6 Month Contact)</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn After Vax 1 (6 Month Contact)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn Before Vax 2</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vax 2</title>
              <participants_list>
                <participants group_id="P1" count="427"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Vax 2 (6 Month Contact)</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC - Group 1.1 or 1.2</title>
          <description>Group 1.1: 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1; or Group 1.2: 13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="B2">
          <title>23vPS - Group 2</title>
          <description>Group 2: 23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="478"/>
            <count group_id="B2" value="237"/>
            <count group_id="B3" value="715"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="1.4"/>
                    <measurement group_id="B2" value="61.7" spread="1.4"/>
                    <measurement group_id="B3" value="61.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Evaluable immunogenicity population: participants who were eligible for the study, adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations. GMTs were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 23vPS</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population: participants who were eligible for the study, adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations. GMTs were calculated using all participants with available data for the specified blood draw.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="123.7" upper_limit="176.5"/>
                    <measurement group_id="O2" value="148" lower_limit="117.9" upper_limit="185.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="108.6" upper_limit="143.4"/>
                    <measurement group_id="O2" value="80" lower_limit="67.5" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1385" lower_limit="1171.2" upper_limit="1638.7"/>
                    <measurement group_id="O2" value="1357" lower_limit="1023.0" upper_limit="1799.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" lower_limit="161.4" upper_limit="246.2"/>
                    <measurement group_id="O2" value="140" lower_limit="107.0" upper_limit="183.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215" lower_limit="965.4" upper_limit="1528.3"/>
                    <measurement group_id="O2" value="706" lower_limit="522.1" upper_limit="954.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537" lower_limit="422.4" upper_limit="682.6"/>
                    <measurement group_id="O2" value="331" lower_limit="233.5" upper_limit="469.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373" lower_limit="268.4" upper_limit="517.6"/>
                    <measurement group_id="O2" value="288" lower_limit="198.0" upper_limit="419.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622" lower_limit="485.7" upper_limit="796.4"/>
                    <measurement group_id="O2" value="734" lower_limit="543.6" upper_limit="990.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1062" lower_limit="863.2" upper_limit="1307.6"/>
                    <measurement group_id="O2" value="789" lower_limit="586.2" upper_limit="1062.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467" lower_limit="403.5" upper_limit="541.0"/>
                    <measurement group_id="O2" value="376" lower_limit="302.8" upper_limit="465.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774" lower_limit="642.0" upper_limit="933.6"/>
                    <measurement group_id="O2" value="509" lower_limit="385.5" upper_limit="672.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="151.2" upper_limit="259.4"/>
                    <measurement group_id="O2" value="70" lower_limit="49.9" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] - [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>4.35</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS]).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 23vPS</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data for the specified blood draw.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="123.7" upper_limit="176.5"/>
                    <measurement group_id="O2" value="77" lower_limit="60.7" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="108.6" upper_limit="143.4"/>
                    <measurement group_id="O2" value="50" lower_limit="40.9" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1385" lower_limit="1171.2" upper_limit="1638.7"/>
                    <measurement group_id="O2" value="935" lower_limit="739.9" upper_limit="1182.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" lower_limit="161.4" upper_limit="246.2"/>
                    <measurement group_id="O2" value="85" lower_limit="64.2" upper_limit="112.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215" lower_limit="965.4" upper_limit="1528.3"/>
                    <measurement group_id="O2" value="710" lower_limit="529.1" upper_limit="953.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537" lower_limit="422.4" upper_limit="682.6"/>
                    <measurement group_id="O2" value="126" lower_limit="85.6" upper_limit="184.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373" lower_limit="268.4" upper_limit="517.6"/>
                    <measurement group_id="O2" value="114" lower_limit="76.5" upper_limit="169.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622" lower_limit="485.7" upper_limit="796.4"/>
                    <measurement group_id="O2" value="435" lower_limit="323.0" upper_limit="585.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1062" lower_limit="863.2" upper_limit="1307.6"/>
                    <measurement group_id="O2" value="564" lower_limit="418.2" upper_limit="761.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467" lower_limit="403.5" upper_limit="541.0"/>
                    <measurement group_id="O2" value="289" lower_limit="235.7" upper_limit="353.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774" lower_limit="642.0" upper_limit="933.6"/>
                    <measurement group_id="O2" value="286" lower_limit="217.3" upper_limit="376.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="151.2" upper_limit="259.4"/>
                    <measurement group_id="O2" value="124" lower_limit="88.2" upper_limit="173.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.95</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.76</ci_lower_limit>
            <ci_upper_limit>6.61</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.97</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>3.74</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC / 23vPS] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data who had determinate assay values at both the postvaccination 1 (13vPnC; Year 0) and postvaccination 2 (13vPnC / 13vPnC; Year 1) time points.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Vaccination 1 (Year 0)</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC Vaccination 2 (Year 1)</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data who had determinate assay values at both the postvaccination 1 (13vPnC; Year 0) and postvaccination 2 (13vPnC / 13vPnC; Year 1) time points.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215" lower_limit="163.9" upper_limit="282.4"/>
                    <measurement group_id="O2" value="142" lower_limit="112.2" upper_limit="180.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="57.2" upper_limit="94.1"/>
                    <measurement group_id="O2" value="89" lower_limit="75.2" upper_limit="105.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2255" lower_limit="1625.2" upper_limit="3128.6"/>
                    <measurement group_id="O2" value="1214" lower_limit="931.8" upper_limit="1582.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" lower_limit="112.1" upper_limit="258.6"/>
                    <measurement group_id="O2" value="98" lower_limit="69.6" upper_limit="136.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2682" lower_limit="1969.5" upper_limit="3652.1"/>
                    <measurement group_id="O2" value="2281" lower_limit="1747.1" upper_limit="2978.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2112" lower_limit="1508.0" upper_limit="2958.2"/>
                    <measurement group_id="O2" value="1882" lower_limit="1429.7" upper_limit="2477.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="930" lower_limit="602.1" upper_limit="1437.1"/>
                    <measurement group_id="O2" value="323" lower_limit="215.8" upper_limit="482.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919" lower_limit="619.1" upper_limit="1364.0"/>
                    <measurement group_id="O2" value="335" lower_limit="214.6" upper_limit="522.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492" lower_limit="312.7" upper_limit="774.5"/>
                    <measurement group_id="O2" value="384" lower_limit="262.4" upper_limit="561.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1440" lower_limit="1015.3" upper_limit="2043.5"/>
                    <measurement group_id="O2" value="986" lower_limit="730.8" upper_limit="1330.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583" lower_limit="426.6" upper_limit="796.8"/>
                    <measurement group_id="O2" value="385" lower_limit="308.2" upper_limit="481.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566" lower_limit="385.7" upper_limit="829.2"/>
                    <measurement group_id="O2" value="502" lower_limit="381.3" upper_limit="662.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291" lower_limit="187.7" upper_limit="452.2"/>
                    <measurement group_id="O2" value="456" lower_limit="322.4" upper_limit="644.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data who had determinate assay values at both the postvaccination 1 (13vPnC; Year 0) and postvaccination 2 (13vPnC / 23vPS; Year 1) time points.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Vaccination 1 (Year 0)</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS Vaccination 2 (Year 1)</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data who had determinate assay values at both the postvaccination 1 (13vPnC; Year 0) and postvaccination 2 (13vPnC / 23vPS; Year 1) time points.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" lower_limit="178.9" upper_limit="269.3"/>
                    <measurement group_id="O2" value="140" lower_limit="117.4" upper_limit="168.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="61.3" upper_limit="88.7"/>
                    <measurement group_id="O2" value="129" lower_limit="112.4" upper_limit="147.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2517" lower_limit="2091.7" upper_limit="3029.2"/>
                    <measurement group_id="O2" value="1430" lower_limit="1214.7" upper_limit="1683.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" lower_limit="170.9" upper_limit="300.5"/>
                    <measurement group_id="O2" value="188" lower_limit="151.1" upper_limit="234.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2012" lower_limit="1571.9" upper_limit="2574.1"/>
                    <measurement group_id="O2" value="1351" lower_limit="1087.6" upper_limit="1677.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1252" lower_limit="971.1" upper_limit="1614.4"/>
                    <measurement group_id="O2" value="533" lower_limit="419.2" upper_limit="678.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758" lower_limit="563.8" upper_limit="1018.9"/>
                    <measurement group_id="O2" value="406" lower_limit="292.3" upper_limit="564.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664" lower_limit="485.1" upper_limit="908.5"/>
                    <measurement group_id="O2" value="616" lower_limit="473.3" upper_limit="802.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1532" lower_limit="1183.7" upper_limit="1982.7"/>
                    <measurement group_id="O2" value="1074" lower_limit="871.7" upper_limit="1322.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696" lower_limit="581.1" upper_limit="833.6"/>
                    <measurement group_id="O2" value="457" lower_limit="389.5" upper_limit="536.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696" lower_limit="546.3" upper_limit="887.7"/>
                    <measurement group_id="O2" value="773" lower_limit="636.6" upper_limit="937.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358" lower_limit="265.5" upper_limit="481.7"/>
                    <measurement group_id="O2" value="216" lower_limit="165.0" upper_limit="282.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: geometric mean fold rise (GMFR) calculated using all evaluable participants with data from both the postvaccination 1 and postvaccination 2 blood draws.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion on which to declare non-inferiority = lower bound of the 2-sided 95% confidence interval for the geometric mean fold rise greater than 0.5.</non_inferiority_desc>
            <param_type>Geometric mean fold rise</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
            <estimate_desc>CIs are back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 23vPS / 13vPnC (Year 1) Versus 13vPnC (Year 0)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data for the specified blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 23vPS / 13vPnC (Year 1) Versus 13vPnC (Year 0)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. GMTs were calculated using all participants with available data for the specified blood draw.</population>
          <units>geometric mean titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" lower_limit="177.7" upper_limit="240.9"/>
                    <measurement group_id="O2" value="77" lower_limit="60.7" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="66.0" upper_limit="85.3"/>
                    <measurement group_id="O2" value="50" lower_limit="40.9" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2536" lower_limit="2192.3" upper_limit="2933.0"/>
                    <measurement group_id="O2" value="935" lower_limit="739.9" upper_limit="1182.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215" lower_limit="175.9" upper_limit="261.7"/>
                    <measurement group_id="O2" value="85" lower_limit="64.2" upper_limit="112.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1948" lower_limit="1614.0" upper_limit="2351.7"/>
                    <measurement group_id="O2" value="710" lower_limit="529.1" upper_limit="953.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1063" lower_limit="868.6" upper_limit="1302.2"/>
                    <measurement group_id="O2" value="126" lower_limit="85.6" upper_limit="184.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="767" lower_limit="620.0" upper_limit="949.3"/>
                    <measurement group_id="O2" value="114" lower_limit="76.5" upper_limit="169.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650" lower_limit="524.9" upper_limit="805.8"/>
                    <measurement group_id="O2" value="435" lower_limit="323.0" upper_limit="585.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1576" lower_limit="1321.3" upper_limit="1880.9"/>
                    <measurement group_id="O2" value="564" lower_limit="418.2" upper_limit="761.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709" lower_limit="618.9" upper_limit="811.2"/>
                    <measurement group_id="O2" value="289" lower_limit="235.7" upper_limit="353.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="711" lower_limit="595.9" upper_limit="848.9"/>
                    <measurement group_id="O2" value="286" lower_limit="217.3" upper_limit="376.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354" lower_limit="283.8" upper_limit="440.7"/>
                    <measurement group_id="O2" value="124" lower_limit="88.2" upper_limit="173.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>3.61</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.94</ci_lower_limit>
            <ci_upper_limit>3.88</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.68</ci_lower_limit>
            <ci_upper_limit>12.60</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.45</ci_lower_limit>
            <ci_upper_limit>10.22</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.01</ci_lower_limit>
            <ci_upper_limit>3.89</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: ratio for GMT calculated by back transformation of the mean difference between vaccine groups on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titer</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ([13vPnC] – [23vPS / 13vPnC]).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS</title>
        <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population includes all participants who receive at least 1 dose of study vaccine. N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC and 23vPS, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS</title>
          <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
          <population>Safety population includes all participants who receive at least 1 dose of study vaccine. N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC and 23vPS, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=270, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=266, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=264, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=259, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=270, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=268, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=263, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=258, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=370, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=360, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1"/>
                    <measurement group_id="O2" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=284, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=261, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=289, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=286, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=260, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=261, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)</title>
        <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC and 13vPnC / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)</title>
          <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
          <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC and 13vPnC / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=58, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=60, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=59, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=55, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=56, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=108, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=101, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3"/>
                    <measurement group_id="O2" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=56, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=56, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)</title>
        <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC and 23vPS / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)</title>
          <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
          <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC and 23vPS / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=270, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=266, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=264, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=259, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=270, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=268, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=263, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=258, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=370, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=360, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1"/>
                    <measurement group_id="O2" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=284, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=261, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=289, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=286, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=260, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=261, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)</title>
        <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]); Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 23vPS and 13vPnC / 23vPS, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>23vPS</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)</title>
          <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]); Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
          <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 23vPS and 13vPnC / 23vPS, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=134, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=134, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=128, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=127, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=135, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=132, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=132, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=127, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=175, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=170, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=143, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=127, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=142, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=142, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=127, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=128, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC</title>
        <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
        <time_frame>14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
          <group group_id="O3">
            <title>23vPS / 13vPnC</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC</title>
          <description>Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
          <population>Safety population; N=number of participants with any local reaction; (n)=number of participants with known values for 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=86, 151, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=83, 144, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=83, 138, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=83, 131, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=86, 155, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="25.8"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=85, 149, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="20.1"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=82, 138, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=82, 132, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=129, 231, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=123, 205, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="78.5"/>
                    <measurement group_id="O3" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=91, 176, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="49.4"/>
                    <measurement group_id="O3" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=83, 140, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=93, 178, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="53.4"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=92, 171, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate(n=83,134,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=82, 135,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="8.1"/>
                    <measurement group_id="O3" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS</title>
        <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1])</time_frame>
        <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC and 23vPS, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS</title>
          <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
          <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC and 23vPS, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any ≥38 degrees C (n=263, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild ≥38 but &lt;38.5 degrees C (n=263, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate ≥38.5 but &lt;39 degrees C(n=259,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe ≥39 but ≤40 degrees C (n=259, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Potentially life threatening &gt;40C(n=258,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=321, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                    <measurement group_id="O2" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=328, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7"/>
                    <measurement group_id="O2" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=286, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9"/>
                    <measurement group_id="O2" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=267, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=261, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=278, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=324, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=286, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=278, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=272, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)</title>
        <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC and 13vPnC / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)</title>
          <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
          <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC and 13vPnC / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any ≥38 degrees C (n=55, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild ≥38 but &lt;38.5 degrees C (n=55, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate ≥38.5 but &lt;39 degrees C(n=55, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe ≥39 but ≤40 degrees C (n=55, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Potentially life threatening &gt;40C (n=55, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=76, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6"/>
                    <measurement group_id="O2" value="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=76, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6"/>
                    <measurement group_id="O2" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=60, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=56, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=84, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=68, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=62, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=62, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)</title>
        <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC and 23vPS / 13vPnC , respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>23vPS / 13vPnC</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)</title>
          <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
          <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC and 23vPS / 13vPnC , respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any ≥38 degrees C (n=263, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild ≥38 but &lt;38.5 degrees C (n=263, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate ≥38.5 but &lt;39 degrees C(n=259,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe ≥39 but ≤40 degrees C(n=259,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Potentially life threatening &gt;40C(n=258,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=321, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                    <measurement group_id="O2" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=328, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7"/>
                    <measurement group_id="O2" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=286, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9"/>
                    <measurement group_id="O2" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=267, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=261, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=278, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=324, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=286, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=278, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=272, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)</title>
        <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
        <time_frame>14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 23vPS and 13vPnC / 23vPS, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>23vPS</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)</title>
          <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
          <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 23vPS and 13vPnC / 23vPS, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any ≥38 degrees C (n=127, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild ≥38 but &lt;38.5 degrees C (n=127, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate ≥38.5 but &lt;39 degrees C(n=127,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe ≥39 but ≤40 degrees C(n=127,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Potentially life threatening &gt;40C(n=127,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=173, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=167, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1"/>
                    <measurement group_id="O2" value="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=145, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                    <measurement group_id="O2" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=134, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=131, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=148, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=167, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5"/>
                    <measurement group_id="O2" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=154, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=147, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=142, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC</title>
        <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
        <time_frame>14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)</time_frame>
        <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC / 13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC / 23vPS</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0. 23-valent polysaccharide vaccine (23vPS) administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
          <group group_id="O3">
            <title>23vPS / 13vPnC</title>
            <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC</title>
          <description>Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.</description>
          <population>Safety population; N=number of participants with any systemic event; (n)=number of participants with known values for 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC, respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: Any ≥38 degrees C (n=81, 129, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Mild ≥38 but &lt;38.5 degrees C (n=81,129,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Moderate ≥38.5, &lt;39 degrees C(n=81,127,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Severe ≥39, ≤40 degrees C(n=81,127,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potentially life threatening &gt;40C(n=81,127,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=100, 185, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=96, 175, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="49.7"/>
                    <measurement group_id="O3" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=90, 155, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=86, 146, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=82, 131, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=89, 141, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=108, 196, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="61.2"/>
                    <measurement group_id="O3" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=94, 164, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="41.5"/>
                    <measurement group_id="O3" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=87, 153, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="25.5"/>
                    <measurement group_id="O3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=91, 143, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Informed consent through 6 Month Follow-up after last vaccination. Local reactions and systemic events assessed within 14 days after vaccination 1 (Vax 1=Day 1/Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1).</time_frame>
      <desc>Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may=serious for 1 subject and=non-serious for another subject or subject may have experienced both a serious and non-serious episode of same event. AEs/SAEs=non-systematic assessment; local reactions and systemic events=systematic assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC (Year 0)</title>
          <description>Group 1.1: 13vPnC administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1; or Group 1.2: 13vPnC administered as a single dose 0.5 mL IM at Year 0. 23vPS administered as a single dose 0.5 mL IM at Year 1.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=90; systematic (solicited) Local Reactions N=256; systematic (solicited) Systemic Events N=163.</description>
        </group>
        <group group_id="E2">
          <title>23vPS (Year 0)</title>
          <description>Group 2: 23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=49; systematic (solicited) Local Reactions N=102; systematic (solicited) Systemic Events N=86.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC: 6 Month Follow-up After Vax 1 (Year 0)</title>
          <description>Group 1.1: 13vPnC administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1; or Group 1.2: 13vPnC administered as a single dose 0.5 mL IM at Year 0. 23vPS administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="E4">
          <title>23vPS: 6 Month Follow-up After Vax 1 (Year 0)</title>
          <description>Group 2: 23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC / 13vPnC (Year 1)</title>
          <description>13vPnC administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=22; systematic (solicited) Local Reactions N=97; systematic (solicited) Systemic Events N=54.</description>
        </group>
        <group group_id="E6">
          <title>13vPnC / 23vPS (Year 1)</title>
          <description>13vPnC administered as a single dose 0.5 mL IM at Year 0. 23vPS administered as a single dose 0.5 mL IM at Year 1.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=50; systematic (solicited) Local Reactions N=198; systematic (solicited) Systemic Events N=120.</description>
        </group>
        <group group_id="E7">
          <title>23vPS / 13vPnC (Year 1)</title>
          <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=32; systematic (solicited) Local Reactions N=118; systematic (solicited) Systemic Events N=68.</description>
        </group>
        <group group_id="E8">
          <title>13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)</title>
          <description>13vPnC administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="E9">
          <title>13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1)</title>
          <description>13vPnC administered as a single dose 0.5 mL IM at Year 0. 23vPS administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
        <group group_id="E10">
          <title>23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1)</title>
          <description>23vPS administered as a single dose 0.5 mL IM at Year 0. 13vPnC administered as a single dose 0.5 mL IM at Year 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ovarian adhesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="198" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="118" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Mixed hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastrointestinal malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Androgen deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Fever (Any) ≥38 degrees C</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Fever (Mild) ≥38 but &lt;38.5 degrees C</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Fever (Moderate) ≥38.5 but &lt;39 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Fever (Severe) ≥39 but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Fever (Potentially life threatening) &gt;40C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Fatigue</description>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Headache</description>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Chills</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Rash</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Vomiting</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; New generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Aggravated generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; New generalized joint pain</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Aggravated generalized joint pain</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Fever (Any)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Fever (Mild)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Fever (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Fever (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Fever (Potentially life threatening)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Fatigue</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Headache</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Chills</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Rash</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Vomiting</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Decreased appetite</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); New generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Aggravated generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); New generalized joint pain</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Aggravated generalized joint pain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Fever (Any)</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Fever (Mild)</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Fever (Moderate)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Fever (Severe)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Fever (Potentially life threatening)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Fatigue</description>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="58" subjects_at_risk="141"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Headache</description>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="56" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Chills</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="127"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Rash</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Vomiting</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Decreased appetite</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); New generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="68" subjects_at_risk="151"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Aggravated generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); New generalized joint pain</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="128"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Aggravated generalized joint pain</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Fever (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Fever (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Fever (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Fever (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Fever (Potentially life threatening)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Fatigue</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="96" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Headache</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="87" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Chills</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="155"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Rash</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="146"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Vomiting</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Decreased appetite</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); New generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="120" subjects_at_risk="196"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Aggravated generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="68" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); New generalized joint pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="153"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Aggravated generalized joint pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Fever (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Fever (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Fever (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Fever (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (Potentially life threatening)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Fever (Potentially life threatening)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Fatigue</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="96" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="58" subjects_at_risk="141"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Headache</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="87" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="56" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Chills</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="155"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="127"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Rash</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="146"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Vomiting</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Decreased appetite</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); New generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="120" subjects_at_risk="196"/>
                <counts group_id="E7" subjects_affected="68" subjects_at_risk="151"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Aggravated generalized muscle pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="68" subjects_at_risk="164"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); New generalized joint pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="153"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="128"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Aggravated generalized joint pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vascular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Body temperature decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bursa disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nodal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sleep disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sleep disorder due to general medical condition, insomnia type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Xanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Precancerous skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Redness (Any) redness present</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Redness (Mild) 2.5 to 5.0 cm</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Redness (Moderate) 5.1 to 10.0 cm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="264"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Redness (Severe) &gt;10 cm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Swelling (Any) swelling present</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Swelling (Mild) 2.5 to 5.0 cm</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Swelling (Moderate) 5.1 to 10.0 cm</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Swelling (Severe) &gt;10 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Pain (Any) pain present</description>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Pain (Mild) awareness of pain; easily tolerated</description>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Pain (Moderate) discomfort enough to cause interference with usual activity</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="143"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Pain (Severe) incapacitating</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Limitation of arm movement (Any) limitation present</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Limitation of arm movement (Mild) some limitation</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Limitation of arm movement (Moderate) unable to move arm above head; able to move arm above shoulder</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC and 23vPS Year 0; Limitation of arm movement (Severe) unable to move arm above shoulder</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Redness (Any)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Redness (Mild)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Redness (Moderate)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Redness (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Swelling (Any)</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Swelling (Mild)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Swelling (Moderate)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Swelling (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Pain (Any)</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Pain (Mild)</description>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Pain (Moderate)</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Pain (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Limitation of arm movement (Any)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Limitation of arm movement (Mild)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Limitation of arm movement (Moderate)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1); Limitation of arm movement (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Redness (Any)</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Redness (Mild)</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Redness (Moderate)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="264"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Redness (Severe)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Swelling (Any)</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Swelling (Mild)</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Swelling (Moderate)</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Swelling (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Pain (Any)</description>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="118" subjects_at_risk="169"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Pain (Mild)</description>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="113" subjects_at_risk="166"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Pain (Moderate)</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="129"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Pain (Severe)</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Any)</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="130"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Mild)</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="130"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Moderate)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC (Year 0) and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Severe)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Redness (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="151"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Redness (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="144"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Redness (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Redness (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Swelling (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="155"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Swelling (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="149"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Swelling (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Swelling (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Pain (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="198" subjects_at_risk="231"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Pain (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="161" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Pain (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="143"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="87" subjects_at_risk="176"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Pain (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="140"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Limitation of arm movement (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="178"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Limitation of arm movement (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="171"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Limitation of arm movement (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>23vPS (Year 0) and 13vPnC / 23vPS (Year 1); Limitation of arm movement (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Redness (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="151"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Redness (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="144"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Redness (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Redness (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Swelling (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="155"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Swelling (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="149"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Swelling (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Swelling (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Pain (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="129"/>
                <counts group_id="E6" subjects_affected="198" subjects_at_risk="231"/>
                <counts group_id="E7" subjects_affected="118" subjects_at_risk="169"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Pain (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="89" subjects_at_risk="123"/>
                <counts group_id="E6" subjects_affected="161" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="113" subjects_at_risk="166"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Pain (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="87" subjects_at_risk="176"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="129"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Pain (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="140"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Any)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="93"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="178"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="130"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Mild)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="171"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="130"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Moderate)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>13vPnC / 13vPnC (Year 1), 13vPnC / 23vPS (Year 1), and 23vPS / 13vPnC (Year 1); Limitation of arm movement (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Postmenopause</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Venous valve ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="478"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

